LIXTE Biotechnology Holdings, Inc. reports clinical-stage oncology developments centered on LB-100, its proprietary first-in-class PP2A inhibitor. Company updates commonly address proof-of-concept studies in ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma, including combinations designed to enhance chemotherapy or immunotherapy activity.
Recurring announcements also cover the completed acquisition of Liora Technologies Europe Ltd., the LiGHT System proton therapy platform, subsidiary leadership and governance changes, capital actions, annual-report highlights, scientific conference presentations and sponsored health-related events tied to the company's cancer-treatment focus.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.